There’s no approved medication to treat patients with epilepsy so severe that they must be put into a coma to stop their seizures. An experimental drug from Sage Therapeutics (SAGE) aims to fill that void — if the key phase 3 clinical trial yields positive results. It’s expected to read out results within the next month.
It’ll be a pivotal moment not just for the patients, but for Sage and its investors. Here are seven things to know about Sage, which is based in Cambridge, Mass., and its epilepsy drug, brexanolone:
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
na
Evertime I think too much epilepsy attacks me,so I wanna know how to reduce stress and stop thinking too much.